Additional analysis from the CLEAR OUTCOMES trial presented at the European Society of Cardiology Congress 2023 and subsequently published in JAMA Cardiology and Lancet Diabetes Endocrinology further support the long-term use of bempedoic acid in patients at high-risk of cardiovascular events including those with diabetes. In this interview, Stephen J. Nicholls MBBS, PhD, FACC and Erin D. Michos, MD, MHS, FACC, discuss the total events analysis and the stratified analyses across the glycemia spectrum from the CLEAR Outcomes trial.

This ACCEL episode is part of an ACC course titled Bempedoic Acid: New Evidence Transforming the LDL-C Treatment Landscape. Educational grant support is provided by Esperion. More content is available here.

Related References:

1. Nissen SE, Lincoff AM, Brennan D, et al. Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients. N Engl J Med. 2023;388:1353-1364. doi: 10.1056/NEJMoa2215024
2. Nicholls SJ, Nelson AJ, Lincoff AM, et al. Impact of Bempedoic Acid on Total Cardiovascular Events: A Prespecified Analysis of the CLEAR Outcomes Randomized Clinical Trial [published correction appears in JAMA Cardiol. 2024 Jul 1;9(7):674. doi: 10.1001/jamacardio.2024.1279.]. JAMA Cardiol. 2024;9(3):245-253. doi:10.1001/jamacardio.2023.5155
3. Ray KK, Nicholls SJ, Li N, et al. Efficacy and safety of bempedoic acid among patients with and without diabetes: prespecified analysis of the CLEAR Outcomes randomised trial. Lancet Diabetes Endocrinol. 2024;12(1):19-28. doi:10.1016/S2213-8587(23)00316-9.